Holdings
Tri Locum Partners LP
As of Jun 30, 2026, Tri Locum Partners LP reported 17 positions worth US$691M. Largest: Johnson & Johnson, Vertex Pharmaceuticals Incorporated and Eli Lilly And Company. What it bought and sold, with each filing.
| Company | Shares | Value as reported | Change | As of |
|---|---|---|---|---|
| Johnson & Johnson | 425K | US$108M | +10,442 | Jun 30, 2026 |
| Vertex Pharmaceuticals Incorporated | 202K | US$100M | +72,477 | Jun 30, 2026 |
| Eli Lilly And Company | 76,532 | US$91.8M | +14,737 | Jun 30, 2026 |
| Dexcom, Inc. | 820K | US$55.3M | +122K | Jun 30, 2026 |
| Axsome Therapeutics, Inc. | 219K | US$53.7M | +157K | Jun 30, 2026 |
| Enliven Therapeutics, Inc. | 867K | US$44M | new | Jun 30, 2026 |
| Argenx Se | 41,596 | US$38.6M | +9,961 | Jun 30, 2026 |
| Madrigal Pharmaceuticals, Inc. | 68,273 | US$36.7M | −35,015 | Jun 30, 2026 |
| Revolution Medicines, Inc. | 152K | US$28.4M | new | Jun 30, 2026 |
| United Therapeutics Corporation | 47,026 | US$25.5M | −23,344 | Jun 30, 2026 |